STOCK TITAN

Viridian Therapeutics (VRDN) Financials

VRDN NASDAQ
Trailing 12 months to September 30, 2026
Revenue $26.3M -62.8% YoY
Net Income -$453.6M n/m YoY
Free Cash Flow -$343.4M n/m YoY
Operating Cash Flow -$341.5M n/m YoY
Market Cap $3.4B as of Nov 18, 2026
Price / Sales 130x on $26.3M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 5.9x on $580.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VRDN SEC filings page.

Viridian Therapeutics, Inc. (VRDN) reported $26.3M in revenue over the twelve months to Sep 30, 2026, down 62.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VRDN FY2025

Viridian remains a research-funded business: FY2025 revenue reached $70.8M, but cash outflows still dominate operations.

The revenue step-up from $302K in FY2024 to $70.8M in FY2025 did not make operations self-funding. A net loss of $342.6M coincided with operating cash flow of -$276.4M, showing that reported losses remain closely tied to cash consumption rather than being primarily noncash.

R&D consumed $338.9M and equaled 478.4% of revenue, indicating a cost structure built around advancing programs before recurring sales can absorb it. SG&A added $95.3M, reinforcing that current revenue is far below the scale of the operating platform.

The balance sheet is still mostly equity-funded: liabilities were 19.7% of assets, while current assets supported a 12.6x current ratio. Yet financing cash flow of $426.7M alongside operating cash flow of -$276.4M shows reported liquidity was built chiefly through external funding, not receipts from operations.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 69 / 100
Financial Health Score 69/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Viridian Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
65

Viridian Therapeutics, Inc. held $874.7M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $276.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Viridian Therapeutics, Inc. scores 65/100 among other emerging companies.

Dilution
32

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Viridian Therapeutics, Inc. scores 32/100 on it among other emerging companies.

R&D Intensity
95

Viridian Therapeutics, Inc. spent $338.9M on research and development in fiscal year 2025, which was 78.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Viridian Therapeutics, Inc. scores 95/100 among other emerging companies.

Revenue Progress
98

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Viridian Therapeutics, Inc. scores 98/100 on it among other emerging companies.

Burn Trend
32

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Viridian Therapeutics, Inc. scores 32/100 on it among other emerging companies.

Balance Sheet
89

Viridian Therapeutics, Inc.'s cash, cash equivalents and investments came to $874.7M at the end of fiscal year 2025, against $177.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Viridian Therapeutics, Inc. scores 89/100 among other emerging companies.

Altman Z-Score Safe
9.34

Viridian Therapeutics, Inc. scores 9.34, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $3.4B against total liabilities of $177.3M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/7

Viridian Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Viridian Therapeutics, Inc. reported a net loss of $342.6M while operations used $276.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Viridian Therapeutics, Inc. reported an operating loss of $363.4M against $4.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$25.8M
YoY-63.5%
QoQ+8967.6%
5Y CAGR+162.1%
10Y CAGR+39.3%

Viridian Therapeutics, Inc. generated $25.8M in revenue in Q3 2026. This represents a decrease of 63.5% from the same quarter a year earlier. Against the prior quarter it is up 8967.6%.

EBITDA
-$103.1M
YoYn/m
QoQn/m
5Y CAGRn/m

Viridian Therapeutics, Inc.'s EBITDA was -$103.1M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$101.2M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Viridian Therapeutics, Inc. reported a net loss of $101.2M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$93.1M
YoYn/m
QoQn/m
5Y CAGRn/m

Viridian Therapeutics, Inc. recorded an outflow of $93.1M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$172.9M
YoY+1.9%
QoQ+4.8%
5Y CAGR+4.5%

Viridian Therapeutics, Inc. held $172.9M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
114M
YoY+19.0%
QoQ+0.2%

Viridian Therapeutics, Inc. had 114M shares outstanding in Q3 2026. This represents an increase of 19.0% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
94.1%
YoY-5.9pp

Viridian Therapeutics, Inc.'s gross margin was 94.1% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 5.9 percentage points from the same quarter a year earlier.

Return on Equity
-17.4%
YoY-10.6pp
QoQ+1.8pp
5Y change-10.6pp

Viridian Therapeutics, Inc.'s quarterly ROE was -17.4% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 10.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$70.1M
YoY-18.7%
QoQ-2.1%
5Y CAGR+53.9%
10Y CAGR+37.2%

Viridian Therapeutics, Inc. invested $70.1M in research and development in Q3 2026. This represents a decrease of 18.7% from the same quarter a year earlier. Against the prior quarter it is down 2.1%.

Capital Expenditures
$370K
YoY+191.3%
QoQ-71.7%
5Y CAGR+14.9%

Viridian Therapeutics, Inc. invested $370K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 191.3% from the same quarter a year earlier. Against the prior quarter it is down 71.7%.

Share Buybacks

Not reported for Q3 2026.

VRDN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VRDN quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$25.8M-63.5%$284K+278.7%$141K+95.8%$132K+83.3%$70.6M+81958.1%$75K+4.2%$72K0.0%$72K0.0%
Cost of Revenue$1.5Mn/mN/AN/AN/A$0N/AN/AN/A
Gross Profit$24.2M-65.7%N/AN/AN/A$70.6MN/AN/AN/A
R&D Expenses$70.1M-18.7%$71.6M-17.4%$77.6M+1.0%$89.2M+24.0%$86.3M+24.7%$86.6M+54.2%$76.8M+87.7%$72.0M+86.6%
SG&A Expenses$57.6M+136.9%$55.0M+171.9%$38.7M+126.2%$33.7M+116.1%$24.3M+68.8%$20.2M+25.8%$17.1M+13.8%$15.6M-52.8%
Operating Income-$103.5Mn/m-$126.3Mn/m-$116.2Mn/m-$122.7Mn/m-$40.0Mn/m-$106.8Mn/m-$93.9Mn/m-$87.5Mn/m
EBITDA-$103.1Mn/m-$126.2Mn/m-$116.0Mn/m-$122.6Mn/m-$39.9Mn/m-$106.7Mn/m-$93.7Mn/m-$87.3Mn/m
Interest Expense$9.3M+1555.9%$8.3M+1516.1%$3.5M+529.5%$3.3M+586.8%$560K+5.9%$514K-13.9%$550K-6.3%$484K+32.6%
Net Income-$101.2Mn/m-$127.1Mn/m-$104.9Mn/m-$120.4Mn/m-$34.6Mn/m-$100.7Mn/m-$86.9Mn/m-$79.7Mn/m
Diluted Shares (Avg)N/AN/AN/AN/A82M+23.1%82M+27.8%81M+33.1%N/A

Not reported in any period shown, so not listed: Income Tax, EPS (Basic), EPS (Diluted).

VRDN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VRDN quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$1.0B+78.2%$1.1B+88.4%$789.0M+19.4%$899.4M+21.1%$577.1M-25.2%$582.3M-0.6%$661.0M+4.9%$742.4M+51.4%
Current Assets$1.0B+77.1%$1.1B+86.8%$784.7M+19.4%$894.2M+21.1%$571.9M-25.5%$578.8M-0.5%$657.2M+4.9%$738.5M+51.8%
Cash & Equivalents$172.9M+1.9%$165.0M+40.6%$176.3M+51.7%$212.4M+113.2%$169.6M-15.3%$117.3M+9.0%$116.2M+26.8%$99.6M-3.1%
Short-Term Investments$782.3M+143.5%$816.5M+83.1%$585.8M+12.6%$662.3M+7.2%$321.3M-41.9%$446.0M-3.8%$520.4M-0.2%$618.0M+65.0%
Inventory$85KN/AN/A$0N/AN/AN/AN/A
Accounts Receivable$29.8MN/AN/A$0N/AN/AN/AN/A
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$448.0M+504.0%$435.1M+548.0%$153.0M+170.8%$177.3M+150.5%$74.2M+15.2%$67.2M+19.2%$56.5M+18.1%$70.8M+46.2%
Current Liabilities$70.1M+38.2%$63.8M+21.3%$51.8M+53.6%$70.7M+47.7%$50.7M+22.6%$52.6M+43.0%$33.7M+29.1%$47.9M+79.7%
Non-Current Liabilities$377.9M+1510.1%$371.3M+2448.7%$101.2M+344.2%$106.6M+365.5%$23.5M+1.9%$14.6M-25.5%$22.8M+4.9%$22.9M+5.2%
Long-Term DebtN/AN/AN/AN/A$20.9M+1.8%$12.4M-29.4%$20.7M+1.8%$20.6M+1.9%
Total Equity$580.7M+15.5%$662.1M+28.5%$636.0M+5.2%$722.2M+7.5%$503.0M-28.9%$515.2M-2.7%$604.5M+3.8%$671.6M+51.9%
Retained Earnings-$1.7Bn/m-$1.6Bn/m-$1.4Bn/m-$1.3Bn/m-$1.2Bn/m-$1.2Bn/m-$1.1Bn/m-$995.9Mn/m

Not reported in any period shown, so not listed: Goodwill.

VRDN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VRDN quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$92.8Mn/m-$105.3Mn/m-$119.7Mn/m-$23.8Mn/m-$84.6Mn/m-$75.4Mn/m-$92.7Mn/m-$73.3Mn/m
Depreciation & Amortization$343K+211.8%$117K+3.5%$121K+3.4%$120K-2.4%$110K-15.4%$113K-20.4%$117K-19.3%$123K-18.0%
Stock-Based Compensation$17.2M+53.2%$17.0M+56.6%$13.4M+31.0%N/A$11.3M+29.0%$10.8M-7.8%$10.2M-19.5%N/A
Capital Expenditures$370K+191.3%$1.3M+3009.5%$23K-73.3%$240K+110.5%$127K-56.7%$42K-59.6%$86Kn/m$114K+137.5%
Free Cash Flow-$93.1Mn/m-$106.6Mn/m-$119.7Mn/m-$24.0Mn/m-$84.7Mn/m-$75.4Mn/m-$92.7Mn/m-$73.4Mn/m
Investing Cash Flow$24.3M-80.7%-$231.2M-405.3%$77.3M-22.8%-$339.4Mn/m$126.1Mn/m$75.7M+22.2%$100.1Mn/m-$62.9Mn/m
Financing Cash Flow$77.6M+614.8%$325.1M+42455.1%$6.4M-31.0%$405.9M+1042.6%$10.9M-95.6%$764K+607.4%$9.2M-94.8%$35.5M-82.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

VRDN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VRDN quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin94.1%-5.9ppN/AN/AN/A100.0%N/AN/AN/A
Operating Margin-401.8%-44460.6%-82389.4%-92991.7%-56.7%-142356.0%-130369.4%-121487.5%
Net Margin-393.0%-44760.2%-74397.9%-91178.0%-49.0%-134313.3%-120711.1%-110729.2%
Return on Equity-17.4%-10.6pp-19.2%+0.4pp-16.5%-2.1pp-16.7%-4.8pp-6.9%+4.0pp-19.6%-7.3pp-14.4%-6.1pp-11.9%+3.3pp
Return on Assets-9.8%-3.9pp-11.6%+5.7pp-13.3%-0.2pp-13.4%-2.6pp-6.0%+4.0pp-17.3%-6.2pp-13.2%-5.5pp-10.7%+2.9pp
Current Ratio14.46+3.2x16.95+5.9x15.15-4.3x12.65-2.8x11.28-7.3x11.01-4.8x19.49-4.5x15.43-2.8x
Debt-to-EquityN/AN/AN/AN/A0.040.0x0.020.0x0.030.0x0.030.0x
Liabilities-to-Equity0.77+0.6x0.66+0.5x0.24+0.1x0.25+0.1x0.15+0.1x0.130.0x0.090.0x0.110.0x
Asset Turnover0.03-0.1x0.000.0x0.000.0x0.000.0x0.12+0.1x0.000.0x0.000.0x0.000.0x
FCF Margin-361.7%-37545.8%-84877.3%-18177.3%-120.1%-100553.3%-128804.2%-102008.3%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Viridian Therapeutics, Inc. VRDN FY2025 $70.8M -$342.6M N/A $3.4B 69/100
Disc Medicine, Inc. IRON FY2025 N/A -$212.2M N/A $3.6B —
Enliven Therapeutics, Inc. ELVN FY2025 N/A -$103.7M N/A $3.3B —
Iovance Biotherapeutics, Inc. IOVA FY2025 $263.5M -$391.0M N/A $3.5B 62/100
Arcutis Biotherapeutics, Inc. ARQT FY2025 $376.1M -$16.1M -4.3% $3.5B 44/100
Legend Biotech Corporation LEGN FY2025 $1.0B -$296.8M -28.8% $3.2B 50/100

Frequently Asked Questions

Viridian Therapeutics, Inc. (VRDN) reported $70.8M in total revenue for fiscal year 2025. This represents a 23359.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Viridian Therapeutics, Inc. (VRDN) revenue grew by 23359.9% year-over-year, from $302K to $70.8M in fiscal year 2025.

No, Viridian Therapeutics, Inc. (VRDN) reported a net loss of $453.6M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $342.6M.

Viridian Therapeutics, Inc. (VRDN) had EBITDA of -$362.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Viridian Therapeutics, Inc. (VRDN) has a return on equity of -47.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Viridian Therapeutics, Inc. (VRDN) recorded an outflow of $276.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Viridian Therapeutics, Inc. (VRDN) recorded an outflow of $276.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Viridian Therapeutics, Inc. (VRDN) had $899.4M in total assets as of fiscal year 2025, including both current and long-term assets.

Viridian Therapeutics, Inc. (VRDN) invested $495K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Viridian Therapeutics, Inc. (VRDN) invested $338.9M in research and development during fiscal year 2025.

Viridian Therapeutics, Inc. (VRDN) had 102M shares outstanding as of fiscal year 2025.

Viridian Therapeutics, Inc. (VRDN) had a current ratio of 12.65 as of fiscal year 2025, which is generally considered healthy.

Viridian Therapeutics, Inc. (VRDN) had a liabilities-to-equity ratio of 0.25 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Viridian Therapeutics, Inc. (VRDN) had a return on assets of -38.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Viridian Therapeutics, Inc. (VRDN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $3.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Viridian Therapeutics, Inc. (VRDN) trades at 130x sales, its market capitalization divided by $26.3M revenue, trailing 12 months to September 30, 2026. The market capitalization is $3.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Viridian Therapeutics, Inc. (VRDN) held $874.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $276.4M over that year. Dividing the one by the other, the reported balance equals about 38 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Viridian Therapeutics, Inc. (VRDN) has an Altman Z-Score of 9.34, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Viridian Therapeutics, Inc. (VRDN) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Viridian Therapeutics, Inc. (VRDN) reported a net loss of $342.6M while operations used $276.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Viridian Therapeutics, Inc. (VRDN) reported an operating loss of $363.4M against $4.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Viridian Therapeutics, Inc. (VRDN) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top